ClinicalTrials.gg
CompletedNCT06582732Updated Oct 15, 2024Results posted

Performance of the Travoprost Intraocular Implant

A Phase 2 interventional study of Travoprost Intracameral Implant exchanged at Month 12 and Travoprost Intracameral Implant exchanged at Month 3 in Glaucoma, Open-Angle and Ocular Hypertension, sponsored by Glaukos Corporation. Completed at 1 site in Armenia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Glaukos Corporation · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 5 months after the study started (first participant enrolled Mar 2021, registered Aug 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
210
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.

Enrollment
12th of 45
210 · median 135
Started
2021
the only one that year
Phase 2
6 of 46
none open now
Registered
44th of 46
by date
Lead sponsor
7 of 46
Glaukos Corporation

Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 12th largest by enrollment of the 45 interventional ones that give a count, is the only one that started in 2021, is one of 6 in phase 2, and was the 44th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing travoprost in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

To evaluate the performance of the Travoprost Intracameral Implant by determining residual drug in explanted implants of the Travoprost Intracameral Implant and by determining aqueous humor concentrations of travoprost free acid at specified timepoints post administration through 24 months

03

Conditions studied

  • Glaucoma, Open-Angle
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of either open angle glaucoma (i.e. primary, pseudoexfoliation, or pigmentary glaucoma) or ocular hypertenson
  • Zero to three topical intraocular pressure lowering medications at the time of Visit 1 (Screening) exam.
  • Best spectacle corrected visual acuity of 16 letters or more correctly read at 4 meters or better in each eye.
  • Open angle as defined by Shaffer grade ≥ 3 at slit-lamp at the planned implantation site

Exclusion criteria

Exclusion Criteria:

  • Traumatic, uveitic, neovascular, or angle-closure glaucoma; or glaucoma associated with vascular disorders
  • Active ocular inflammation, infection or edema
  • dystrophy (e.g., bullous keratopathy, Fuch's dystrophy) or clinically significant guttata
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
210 participants (actual)

Study arms

  • Experimental
    Cohort 1 (12-month exchange)

    Travoprost Intracameral Implant Exchanged at Month 12

    Drug: Travoprost Intracameral Implant exchanged at Month 12

  • Experimental
    Cohort 2 (3-month exchange)

    Travoprost Intracameral Implant Exchanged at Month 3

    Drug: Travoprost Intracameral Implant exchanged at Month 3

  • Experimental
    Cohort 3 (6-month exchange)

    Travoprost Intracameral Implant Exchanged at Month 6

    Drug: Travoprost Intracameral Implant exchanged at Month 6

  • Experimental
    Cohort 4 (24-month exchange)

    Travoprost Intracameral Implant Exchanged at Month 24

    Drug: Travoprost Intracameral Implant exchanged at Month 24

  • Experimental
    Cohort 5 (21-month exchange)

    Travoprost Intracameral Implant Exchanged at Month 21

    Drug: Travoprost intracameral implant exchanged at Month 21

  • Experimental
    Cohort 6 (18-month exchange)

    Travoprost Intracameral Implant Exchanged at Month 18

    Drug: Travoprost intracameral implant exchanged at Month 18

  • Experimental
    Cohort 7 (15-month exchange)

    Travoprost Intracameral Implant Exchanged at Month 15

    Drug: Travoprost intracameral implant exchanged at Month 15

Interventions

06

What researchers measure

Primary outcomes

  1. Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 12 Months Post-administration

    concentration of travoprost free acid (ng/mL) in the aqueous humor 12 months post-administration as assessed by liquid chromatography tandem mass spectrometry (LC-MS/MS)

    Time frame: month 12

  2. Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 3 Months Post-administration

    concentration of travoprost free acid (ng/mL) in the aqueous humor 3 months post-administration as assessed by LC-MS/MS

    Time frame: month 3

  3. Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 6 Months Post-administration

    concentration of travoprost free acid (ng/mL) in the aqueous humor 6 months post-administration as assessed by LC-MS/MS

    Time frame: month 6

  4. Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 24 Months Post-administration

    concentration of travoprost free acid (ng/mL) in the aqueous humor 24 months post-administration as assessed by LC-MS/MS

    Time frame: month 24

  5. Travoprost Free Acid Concentration(ng/mL) in Aqueous Humor 21 Months Post-administration

    concentration of travoprost free acid (ng/mL) in the aqueous humor 21 months post-administration as assessed by LC-MS/MS

    Time frame: month 21

  6. Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 18 Months Post-administration

    concentration of travoprost free acid (ng/mL) in the aqueous humor 18 months post-administration as assessed by LC-MS/MS

    Time frame: month 18

  7. Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 15 Months Post-administration

    concentration of travoprost free acid (ng/mL) in the aqueous humor 15 months post-administration as assessed by LC-MS/MS

    Time frame: month 15

Secondary outcomes

  1. Percent Residual Travoprost in Explanted Implant 12 Months Post-administration

    percent of travoprost compared to baseline in explanted implant 12 months post-administration as assessed by high performance liquid chromatography (HPLC)

    Time frame: month 12

  2. Percent Residual Travoprost in Explanted Implant 3 Months Post-administration

    percent of travoprost compared to baseline in explanted implant 3 months post-administration as assessed by HPLC

    Time frame: month 3

  3. Percent Residual Travoprost in Explanted Implant 6 Months Post-administration

    percent of travoprost compared to baseline in explanted implant 6 months post-administration as assessed by HPLC

    Time frame: month 6

  4. Percent Residual Travoprost in Explanted Implant 24 Months Post-administration

    percent of travoprost compared to baseline in explanted implant 24 months post-administration as assessed by HPLC

    Time frame: month 24

  5. Percent Residual Travoprost in Explanted Implant 21 Months Post-administration

    percent of travoprost compared to baseline in explanted implant 21 months post-administration as assessed by HPLC

    Time frame: month 21

  6. Percent Residual Travoprost in Explanted Implant 18 Months Post-administration

    percent of travoprost compared to baseline in explanted implant 18 months post-administration as assessed by HPLC

    Time frame: month 18

  7. Percent Residual Travoprost in Explanted Implant 15 Months Post-administration

    percent of travoprost compared to baseline in explanted implant 15 months post-administration as assessed by HPLC

    Time frame: month 15

07

Results

Posted Oct 15, 2024
Limitations and caveats
Study was open-label, non-randomized and conducted at a single site; however, the endpoints were objective and analyses of aqueous humor concentrations of travoprost free acid and of residual travoprost in explants were performed by a third party

Participant flow

Initial Study Period
Participant flow — Initial Study Period
MilestoneCohort 1 (12-month Exchange)Cohort 2 (3-month Exchange)Cohort 3 (6-month Exchange)Cohort 4 (24-month Exchange)Cohort 5 (21-month Exchange)Cohort 6 (18-month Exchange)Cohort 7 (15-month Exchange)
Started30303030303030
Completed29292827252928
Not completed1123512
Withdrew: Adverse event0002000
Withdrew: Death1000100
Withdrew: Lost to follow-up0020000
Withdrew: Withdrawal by subject0101312
Withdrew: Moved away0000100
Post-exchange Study Period
Participant flow — Post-exchange Study Period
MilestoneCohort 1 (12-month Exchange)Cohort 2 (3-month Exchange)Cohort 3 (6-month Exchange)Cohort 4 (24-month Exchange)Cohort 5 (21-month Exchange)Cohort 6 (18-month Exchange)Cohort 7 (15-month Exchange)
Started29292827252928
Completed29292827252928
Not completed0000000

Outcome measures

PrimaryTravoprost Free Acid Concentration (ng/mL) in Aqueous Humor 12 Months Post-administration

concentration of travoprost free acid (ng/mL) in the aqueous humor 12 months post-administration as assessed by liquid chromatography tandem mass spectrometry (LC-MS/MS)

Time frame:
month 12
Reported as:
Mean · ng/mL
Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 12 Months Post-administration
ng/mLCohort 1 (12-month Exchange)
Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 12 Months Post-administration5.57 ± 3.02
PrimaryTravoprost Free Acid Concentration (ng/mL) in Aqueous Humor 3 Months Post-administration

concentration of travoprost free acid (ng/mL) in the aqueous humor 3 months post-administration as assessed by LC-MS/MS

Time frame:
month 3
Reported as:
Mean · ng/mL
Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 3 Months Post-administration
ng/mLCohort 2 (3-month Exchange)
Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 3 Months Post-administration4.98 ± 2.50
PrimaryTravoprost Free Acid Concentration (ng/mL) in Aqueous Humor 6 Months Post-administration

concentration of travoprost free acid (ng/mL) in the aqueous humor 6 months post-administration as assessed by LC-MS/MS

Time frame:
month 6
Reported as:
Mean · ng/mL
Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 6 Months Post-administration
ng/mLCohort 3 (6-month Exchange)
Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 6 Months Post-administration3.74 ± 2.22
PrimaryTravoprost Free Acid Concentration (ng/mL) in Aqueous Humor 24 Months Post-administration

concentration of travoprost free acid (ng/mL) in the aqueous humor 24 months post-administration as assessed by LC-MS/MS

Time frame:
month 24
Reported as:
Mean · ng/mL
Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 24 Months Post-administration
ng/mLCohort 4 (24-month Exchange)
Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 24 Months Post-administration3.35 ± 1.51
PrimaryTravoprost Free Acid Concentration(ng/mL) in Aqueous Humor 21 Months Post-administration

concentration of travoprost free acid (ng/mL) in the aqueous humor 21 months post-administration as assessed by LC-MS/MS

Time frame:
month 21
Reported as:
Mean · ng/mL
Travoprost Free Acid Concentration(ng/mL) in Aqueous Humor 21 Months Post-administration
ng/mLCohort 5 (21-month Exchange)
Travoprost Free Acid Concentration(ng/mL) in Aqueous Humor 21 Months Post-administration3.80 ± 1.58
PrimaryTravoprost Free Acid Concentration (ng/mL) in Aqueous Humor 18 Months Post-administration

concentration of travoprost free acid (ng/mL) in the aqueous humor 18 months post-administration as assessed by LC-MS/MS

Time frame:
month 18
Reported as:
Mean · ng/mL
Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 18 Months Post-administration
ng/mLCohort 6 (18-month Exchange)
Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 18 Months Post-administration2.22 ± 1.24
PrimaryTravoprost Free Acid Concentration (ng/mL) in Aqueous Humor 15 Months Post-administration

concentration of travoprost free acid (ng/mL) in the aqueous humor 15 months post-administration as assessed by LC-MS/MS

Time frame:
month 15
Reported as:
Mean · ng/mL
Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 15 Months Post-administration
ng/mLCohort 7 15-month Exchange)
Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 15 Months Post-administration2.03 ± 0.736
SecondaryPercent Residual Travoprost in Explanted Implant 12 Months Post-administration

percent of travoprost compared to baseline in explanted implant 12 months post-administration as assessed by high performance liquid chromatography (HPLC)

Time frame:
month 12
Reported as:
Mean · percentage of initial
Percent Residual Travoprost in Explanted Implant 12 Months Post-administration
percentage of initialCohort 1 (12-month Exchange)
Percent Residual Travoprost in Explanted Implant 12 Months Post-administration50.2 ± 6.58
SecondaryPercent Residual Travoprost in Explanted Implant 3 Months Post-administration

percent of travoprost compared to baseline in explanted implant 3 months post-administration as assessed by HPLC

Time frame:
month 3
Reported as:
Mean · percentage of initial
Percent Residual Travoprost in Explanted Implant 3 Months Post-administration
percentage of initialCohort 2 (3-month Exchange)
Percent Residual Travoprost in Explanted Implant 3 Months Post-administration78.8 ± 3.15
SecondaryPercent Residual Travoprost in Explanted Implant 6 Months Post-administration

percent of travoprost compared to baseline in explanted implant 6 months post-administration as assessed by HPLC

Time frame:
month 6
Reported as:
Mean · percentage of initial
Percent Residual Travoprost in Explanted Implant 6 Months Post-administration
percentage of initialCohort 3 (6-month Exchange)
Percent Residual Travoprost in Explanted Implant 6 Months Post-administration69.8 ± 8.51
SecondaryPercent Residual Travoprost in Explanted Implant 24 Months Post-administration

percent of travoprost compared to baseline in explanted implant 24 months post-administration as assessed by HPLC

Time frame:
month 24
Reported as:
Mean · percentage of initial
Percent Residual Travoprost in Explanted Implant 24 Months Post-administration
percentage of initialCohort 4 (24-month Exchange)
Percent Residual Travoprost in Explanted Implant 24 Months Post-administration16.3 ± 7.88
SecondaryPercent Residual Travoprost in Explanted Implant 21 Months Post-administration

percent of travoprost compared to baseline in explanted implant 21 months post-administration as assessed by HPLC

Time frame:
month 21
Reported as:
Mean · percentage of initial
Percent Residual Travoprost in Explanted Implant 21 Months Post-administration
percentage of initialCohort 5 (21-month Exchange)
Percent Residual Travoprost in Explanted Implant 21 Months Post-administration28.0 ± 5.76
SecondaryPercent Residual Travoprost in Explanted Implant 18 Months Post-administration

percent of travoprost compared to baseline in explanted implant 18 months post-administration as assessed by HPLC

Time frame:
month 18
Reported as:
Mean · percentage of initial
Percent Residual Travoprost in Explanted Implant 18 Months Post-administration
percentage of initialCohort 6 (18-month Exchange)
Percent Residual Travoprost in Explanted Implant 18 Months Post-administration34.8 ± 7.09
SecondaryPercent Residual Travoprost in Explanted Implant 15 Months Post-administration

percent of travoprost compared to baseline in explanted implant 15 months post-administration as assessed by HPLC

Time frame:
month 15
Reported as:
Mean · percentage of initial
Percent Residual Travoprost in Explanted Implant 15 Months Post-administration
percentage of initialCohort 7 (15-month Exchange)
Percent Residual Travoprost in Explanted Implant 15 Months Post-administration38.6 ± 8.23

Adverse events

Collected over initial travoprost intracameral implant period plus 4 weeks post-exchange. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 (12-month Exchange)1/30 (3.3%)1/30 (3.3%)4/30 (13.3%)
Cohort 2 (3-month Exchange)0/30 (0%)0/30 (0%)0/30 (0%)
Cohort 3 (6-month Exchange)0/30 (0%)0/30 (0%)5/30 (16.7%)
Cohort 4 (24-month Exchange)0/30 (0%)0/30 (0%)3/30 (10%)
Cohort 5 (21-month Exchange)1/30 (3.3%)1/30 (3.3%)0/30 (0%)
Cohort 6 (18-month Exchange)0/30 (0%)0/30 (0%)1/30 (3.3%)
Cohort 7 (15-month Exchange)0/30 (0%)0/30 (0%)1/30 (3.3%)
Most frequent serious events
Most frequent serious events
EventCohort 1 (12-month Exchange)Cohort 2 (3-month Exchange)Cohort 3 (6-month Exchange)Cohort 4 (24-month Exchange)Cohort 5 (21-month Exchange)Cohort 6 (18-month Exchange)Cohort 7 (15-month Exchange)
Myocardial infarctionCardiac disorders1/300/300/300/301/300/300/30
Most frequent other events
Most frequent other events
EventCohort 1 (12-month Exchange)Cohort 2 (3-month Exchange)Cohort 3 (6-month Exchange)Cohort 4 (24-month Exchange)Cohort 5 (21-month Exchange)Cohort 6 (18-month Exchange)Cohort 7 (15-month Exchange)
Corona virus infectionInfections and infestations2/300/303/300/300/300/300/30
Intraocular pressure increasedInvestigations2/300/301/302/300/301/300/30
InfluenzaInfections and infestations1/300/300/301/300/300/300/30
PneumoniaInfections and infestations0/300/300/300/300/300/301/30
IridodialysisEye disorders0/300/300/301/300/300/300/30
HyphaemaInjury, poisoning and procedural complications0/300/301/300/300/300/300/30

Baseline characteristics

only a single eye (defined as the study eye) was analyzed in the study

Age, Categorical
Age, Categorical(Participants)Cohort 1 (12-month Exchange)Cohort 2 (3-month Exchange)Cohort 3 (6-month Exchange)Cohort 4 (24-month Exchange)Cohort 5 (21-month Exchange)Cohort 6 (18-month Exchange)Cohort 7 (15-month Exchange)Total
<=18 years00000000
Between 18 and 65 years17141416141612103
>=65 years13161614161418107
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 (12-month Exchange)Cohort 2 (3-month Exchange)Cohort 3 (6-month Exchange)Cohort 4 (24-month Exchange)Cohort 5 (21-month Exchange)Cohort 6 (18-month Exchange)Cohort 7 (15-month Exchange)Total
Female15161415101716103
Male15141615201314107
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1 (12-month Exchange)Cohort 2 (3-month Exchange)Cohort 3 (6-month Exchange)Cohort 4 (24-month Exchange)Cohort 5 (21-month Exchange)Cohort 6 (18-month Exchange)Cohort 7 (15-month Exchange)Total
American Indian or Alaska Native00000000
Asian00000000
Native Hawaiian or Other Pacific Islander00000000
Black or African American00000000
White30303030303030210
More than one race00000000
Unknown or Not Reported00000000
Region of Enrollment
Region of Enrollment(participants)Cohort 1 (12-month Exchange)Cohort 2 (3-month Exchange)Cohort 3 (6-month Exchange)Cohort 4 (24-month Exchange)Cohort 5 (21-month Exchange)Cohort 6 (18-month Exchange)Cohort 7 (15-month Exchange)Total
Armenia30303030303030210
Type of Disease
Type of Disease(Participants)Cohort 1 (12-month Exchange)Cohort 2 (3-month Exchange)Cohort 3 (6-month Exchange)Cohort 4 (24-month Exchange)Cohort 5 (21-month Exchange)Cohort 6 (18-month Exchange)Cohort 7 (15-month Exchange)Total
Open-angle glaucoma30303030303030210
Ocular hypertension00000000
08

Study locations

1 site
  • Glaukos Clinical Study Site
    Yerevan, Armenia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Nov 2023, 31 months.

Results were first posted in Oct 2024, 11 months after primary completion.

Of 38 industry-sponsored phase 2 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's 31 months is above that.

Counting every sponsor, half of 41 studies reached it within 11 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2024
First posted
Sep 3, 2024
StartActual
Mar 10, 2021
Primary completionActual
Nov 2, 2023
CompletionActual
Nov 2, 2023
Results first posted
Oct 15, 2024
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06582732
Responsible party
Sponsor
First posted
Sep 3, 2024
Start date
Mar 10, 2021
Primary completion
Nov 2, 2023
Completion
Nov 2, 2023
Results posted
Oct 15, 2024
Last update
Oct 15, 2024

Study contacts

Kerry Stephens
study director · Glaukos Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Travoprost

Start the discussion